Morpholino

MO2-rad21a

ID
ZDB-MRPHLNO-070904-2
Name
MO2-rad21a
Previous Names
  • MO1-rad21
  • rad21ATGMO (1)
Target
Sequence
5' - AGGACGAAGTGGGCGTAAAACATTG - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO2-rad21a
No data available
Phenotype
Phenotype resulting from MO2-rad21a
Phenotype Fish Figures
atrioventricular valve decreased size, abnormal c262Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
atrioventricular valve non-functional, abnormal c262Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
atrioventricular valve orientation ventriculo bulbo valve, abnormal c262Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
atrium blood decreased amount, abnormal c262Tg; sd2Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
blood circulation decreased process quality, abnormal c262Tg; sd2Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
blood circulation decreased rate, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 1,  Fig. 2 from Schuster et al., 2015
cardiac ventricle blood decreased amount, abnormal c262Tg; sd2Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
cell spindle morphology, abnormal AB + MO2-rad21a Fig. 7 with image from Horsfield et al., 2007
cell population proliferation increased occurrence, abnormal WT + MO2-rad21a Fig. 7 from Xu et al., 2015
cranial cartilage cartilage development disrupted, abnormal WT + MO2-rad21a Fig. 5 from Xu et al., 2015
developmental growth disrupted, abnormal WT + MO2-rad21a Fig. 1 from Schuster et al., 2015
embryo development delayed, abnormal AB + MO2-rad21a Fig. 4 with image from Horsfield et al., 2007
embryo development disrupted, abnormal WT + MO2-rad21a Fig. 8 from Xu et al., 2015
epidermis melanocyte position, abnormal WT + MO2-rad21a Fig. 5 from Schuster et al., 2015
eye decreased size, abnormal WT + MO2-rad21a Fig. 1,  Fig. 8 from Xu et al., 2015
head decreased size, abnormal WT + MO2-rad21a Fig. 1,  Fig. 8 from Xu et al., 2015
head apoptotic process increased occurrence, abnormal WT + MO2-rad21a Fig. 6 from Xu et al., 2015
heart edematous, abnormal WT + MO2-rad21a Fig. 1,  Fig. S7 from Xu et al., 2015
heart malformed, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 1,  Fig. S2,  Fig. S3 from Schuster et al., 2015
heart morphology, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 2 from Schuster et al., 2015
heart cardiac neural crest decreased amount, abnormal WT + MO2-rad21a Fig. 4 from Schuster et al., 2015
heart contraction decreased rate, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 2 from Schuster et al., 2015
Fig. S7 from Xu et al., 2015
heart looping disrupted, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 2 from Schuster et al., 2015
melanocyte mislocalised, abnormal WT + MO2-rad21a Fig. 5 from Schuster et al., 2015
mitotic cell cycle arrested, abnormal AB + MO2-rad21a Fig. 7 with image from Horsfield et al., 2007
mitotic sister chromatid cohesion process quality, abnormal AB + MO2-rad21a Fig. 7 with image from Horsfield et al., 2007
neural tube pigmentation increased occurrence, abnormal WT + MO2-rad21a Fig. 5 from Schuster et al., 2015
nucleate erythrocyte increased accumulation heart, abnormal sd2Tg; zp5Tg + MO2-rad21a Fig. 2 from Schuster et al., 2015
pharyngeal arch aplastic, abnormal ba2Tg + MO2-rad21a Fig. 6 from Schuster et al., 2015
pharyngeal arch disorganized, abnormal ba2Tg + MO2-rad21a Fig. 6 from Schuster et al., 2015
pharyngeal arch morphology, abnormal ba2Tg + MO2-rad21a Fig. 6 from Schuster et al., 2015
post-vent region curved, abnormal WT + MO2-rad21a Fig. 1 from Xu et al., 2015
post-vent region apoptotic process increased occurrence, abnormal WT + MO2-rad21a Fig. 6 from Xu et al., 2015
rRNA transcription decreased process quality, abnormal WT + MO2-rad21a Fig. 4,  Fig. 9 from Xu et al., 2015
translation decreased process quality, abnormal WT + MO2-rad21a Fig. 3,  Fig. 4,  Fig. 9 from Xu et al., 2015
ventriculo bulbo valve aplastic, abnormal c262Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
ventriculo bulbo valve decreased size, abnormal c262Tg + MO2-rad21a Fig. 3 from Schuster et al., 2015
whole organism dead, abnormal WT + MO2-rad21a Fig. 1 from Schuster et al., 2015
whole organism pdgfaa expression decreased amount, abnormal WT + MO2-rad21a Fig. 7 from Schuster et al., 2015
whole organism sema3aa expression decreased amount, abnormal WT + MO2-rad21a Fig. 7 from Schuster et al., 2015
whole organism gja1b expression decreased amount, abnormal WT + MO2-rad21a Fig. 7 from Schuster et al., 2015
whole organism itga9 expression decreased amount, abnormal WT + MO2-rad21a Fig. 7 from Schuster et al., 2015
whole organism bmp3 expression decreased amount, abnormal WT + MO2-rad21a Fig. 7 from Schuster et al., 2015
whole organism sox10 expression decreased amount, abnormal WT + MO2-rad21a Fig. S4 from Schuster et al., 2015
whole organism decreased length, abnormal WT + MO2-rad21a Fig. 1 from Xu et al., 2015
whole organism decreased size, abnormal WT + MO2-rad21a Fig. 1 from Schuster et al., 2015
whole organism deformed, abnormal AB + MO2-rad21a Fig. 8 with image from Muto et al., 2011
whole organism runx1 expression increased amount, abnormal AB + MO2-rad21a FIGURE 4 with image from Mazzola et al., 2020
whole organism tp53 expression increased amount, abnormal WT + MO2-rad21a Fig. 1 from Xu et al., 2015
whole organism spi1b expression increased amount, abnormal AB + MO2-rad21a FIGURE 4 with image from Mazzola et al., 2020
whole organism gata1a expression increased amount, abnormal AB + MO2-rad21a FIGURE 4 with image from Mazzola et al., 2020
whole organism lethal (sensu genetics), abnormal WT + MO2-rad21a Fig. 8,  Fig. S4 from Xu et al., 2015
whole organism morphology, abnormal AB + MO2-rad21a Fig. 4 with image from Horsfield et al., 2007
Phenotype of all Fish created by or utilizing MO2-rad21a
Phenotype Fish Conditions Figures
whole organism gata1a expression increased amount, abnormal AB + MO2-rad21a standard conditions FIGURE 4 with image from Mazzola et al., 2020
mitotic sister chromatid cohesion process quality, abnormal AB + MO2-rad21a standard conditions Fig. 7 with image from Horsfield et al., 2007
cell spindle morphology, abnormal AB + MO2-rad21a standard conditions Fig. 7 with image from Horsfield et al., 2007
embryo development delayed, abnormal AB + MO2-rad21a standard conditions Fig. 4 with image from Horsfield et al., 2007
whole organism deformed, abnormal AB + MO2-rad21a standard conditions Fig. 8 with image from Muto et al., 2011
mitotic cell cycle arrested, abnormal AB + MO2-rad21a standard conditions Fig. 7 with image from Horsfield et al., 2007
whole organism spi1b expression increased amount, abnormal AB + MO2-rad21a standard conditions FIGURE 4 with image from Mazzola et al., 2020
whole organism morphology, abnormal AB + MO2-rad21a standard conditions Fig. 4 with image from Horsfield et al., 2007
whole organism runx1 expression increased amount, abnormal AB + MO2-rad21a standard conditions FIGURE 4 with image from Mazzola et al., 2020
whole organism itga9 expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Schuster et al., 2015
cell population proliferation increased occurrence, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Xu et al., 2015
developmental growth disrupted, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Schuster et al., 2015
cranial cartilage cartilage development decreased process quality, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 5 from Xu et al., 2015
melanocyte mislocalised, abnormal WT + MO2-rad21a standard conditions Fig. 5 from Schuster et al., 2015
heart edematous, abnormal WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. S7 from Xu et al., 2015
whole organism lethal (sensu genetics), ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. S4 from Xu et al., 2015
whole organism pdgfaa expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Schuster et al., 2015
cell population proliferation increased occurrence, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 7 from Xu et al., 2015
head decreased size, ameliorated WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 8 from Xu et al., 2015
whole organism decreased length, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Xu et al., 2015
head apoptotic process increased occurrence, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 6 from Xu et al., 2015
eye decreased size, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 2 from Xu et al., 2015
whole organism bmp3 expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Schuster et al., 2015
whole organism lethal (sensu genetics), abnormal WT + MO2-rad21a standard conditions Fig. 8,  Fig. S4 from Xu et al., 2015
head apoptotic process increased occurrence, abnormal WT + MO2-rad21a standard conditions Fig. 6 from Xu et al., 2015
rRNA transcription decreased process quality, abnormal WT + MO2-rad21a standard conditions Fig. 4,  Fig. 9 from Xu et al., 2015
trunk decreased length, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 2 from Xu et al., 2015
translation decreased process quality, abnormal WT + MO2-rad21a standard conditions Fig. 3,  Fig. 4,  Fig. 9 from Xu et al., 2015
heart malformed, abnormal WT + MO2-rad21a standard conditions Fig. 1,  Fig. S2 from Schuster et al., 2015
eye decreased size, abnormal WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 8 from Xu et al., 2015
cranial cartilage cartilage development disrupted, abnormal WT + MO2-rad21a standard conditions Fig. 5 from Xu et al., 2015
rRNA transcription decreased process quality, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 4 from Xu et al., 2015
post-vent region curved, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 2 from Xu et al., 2015
neural tube pigmentation increased occurrence, abnormal WT + MO2-rad21a standard conditions Fig. 5 from Schuster et al., 2015
whole organism dead, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Schuster et al., 2015
translation decreased process quality, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 3,  Fig. 4 from Xu et al., 2015
heart contraction decreased rate, abnormal WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. S7 from Xu et al., 2015
post-vent region curved, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Xu et al., 2015
heart edematous, abnormal WT + MO2-rad21a standard conditions Fig. 1,  Fig. S7 from Xu et al., 2015
whole organism decreased size, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Schuster et al., 2015
whole organism sema3aa expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Schuster et al., 2015
post-vent region apoptotic process increased occurrence, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 6 from Xu et al., 2015
embryo development disrupted, ameliorated WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 8 from Xu et al., 2015
whole organism gja1b expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 7 from Schuster et al., 2015
head decreased size, abnormal WT + MO2-rad21a standard conditions Fig. 1,  Fig. 8 from Xu et al., 2015
whole organism sox10 expression decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. S4 from Schuster et al., 2015
embryo development disrupted, abnormal WT + MO2-rad21a standard conditions Fig. 8 from Xu et al., 2015
eye decreased size, abnormal WT + MO2-rad21a standard conditions Fig. 1,  Fig. 8 from Xu et al., 2015
whole organism tp53 expression increased amount, abnormal WT + MO2-rad21a standard conditions Fig. 1 from Xu et al., 2015
translation decreased process quality, ameliorated WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 9 from Xu et al., 2015
rRNA transcription decreased process quality, ameliorated WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 9 from Xu et al., 2015
heart contraction decreased rate, abnormal WT + MO2-rad21a standard conditions Fig. S7 from Xu et al., 2015
whole organism lethal (sensu genetics), ameliorated WT + MO2-rad21a chemical treatment: 4-methyl-2-oxopentanoic acid Fig. 8 from Xu et al., 2015
epidermis melanocyte position, abnormal WT + MO2-rad21a standard conditions Fig. 5 from Schuster et al., 2015
heart cardiac neural crest decreased amount, abnormal WT + MO2-rad21a standard conditions Fig. 4 from Schuster et al., 2015
head decreased size, ameliorated WT + MO2-rad21a chemical treatment: L-leucine zwitterion Fig. 2 from Xu et al., 2015
post-vent region apoptotic process increased occurrence, abnormal WT + MO2-rad21a standard conditions Fig. 6 from Xu et al., 2015
heart malformed, abnormal rad21anz171/+ + MO2-rad21a standard conditions Fig. S3 from Schuster et al., 2015
pharyngeal arch morphology, abnormal ba2Tg + MO2-rad21a standard conditions Fig. 6 from Schuster et al., 2015
pharyngeal arch disorganized, abnormal ba2Tg + MO2-rad21a standard conditions Fig. 6 from Schuster et al., 2015
pharyngeal arch aplastic, abnormal ba2Tg + MO2-rad21a standard conditions Fig. 6 from Schuster et al., 2015
atrioventricular valve non-functional, abnormal c262Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
atrioventricular valve decreased size, abnormal c262Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
ventriculo bulbo valve decreased size, abnormal c262Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
atrioventricular valve orientation ventriculo bulbo valve, abnormal c262Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
ventriculo bulbo valve aplastic, abnormal c262Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
cardiac ventricle blood decreased amount, abnormal c262Tg; sd2Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
blood circulation decreased process quality, abnormal c262Tg; sd2Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
atrium blood decreased amount, abnormal c262Tg; sd2Tg + MO2-rad21a standard conditions Fig. 3 from Schuster et al., 2015
heart malformed, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 1 from Schuster et al., 2015
heart looping disrupted, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 2 from Schuster et al., 2015
heart morphology, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 2 from Schuster et al., 2015
nucleate erythrocyte increased accumulation heart, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 2 from Schuster et al., 2015
blood circulation decreased rate, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 1,  Fig. 2 from Schuster et al., 2015
heart contraction decreased rate, abnormal sd2Tg; zp5Tg + MO2-rad21a standard conditions Fig. 2 from Schuster et al., 2015
heart malformed, ameliorated tp53zdf1/zdf1 + MO2-rad21a standard conditions Fig. S2 from Schuster et al., 2015
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.